Personalized Therapy in Pain Management: Where Do We Stand?

• Kehlet H , JensenTS, WoolfCJ: Persistent postsurgical pain: risk factors and prevention.Lancet367(9522) , 1618–1625 (2006).
   PubMed Web of Science ®Google Scholar
• Katz J , SeltzerZ: Transition from acute to chronic postsurgical pain: risk factors and protective factors.Expert Rev. Neurother.9(5) , 723–744 (2009).
   PubMed Web of Science ®Google Scholar
• Skorpen F , LaugsandEA, KlepstadP et al.: Variable response to opioid treatment: any genetic predictors within sight?Palliat. Med.22 , 310–327 (2008).
   PubMed Web of Science ®Google Scholar
• Lötsch J , GeisslingerG, TegederI: Genetic modulation of the pharmacological treatment of pain.Pharmacol Ther.124(2) , 168–184 (2009).
   PubMed Web of Science ®Google Scholar
• Rollason V , SamerC, PiguetV, DayerP, DesmeulesJ: Pharmacogenetics of analgesics: toward the individualization of prescription.Pharmacogenomics9(7) , 905–933 (2008).
   PubMed Web of Science ®Google Scholar
• Smith HS : Variations in opioid responsiveness.Pain Physician11 , 237–248 (2008).
   PubMed Web of Science ®Google Scholar
• Shah RR : Pharmacogenetics in drug regulation: promise, potential and pitfalls.Philos. Trans. R. Soc. Lond. B Biol. Sci.360(1460) , 1617–1638 (2005).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol. Ther.116(3) , 496–526 (2007).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57 , 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• Wang B , YangLP, ZhangXZ, HuangSQ, BartlamM, ZhouSF: New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.Drug Metab. Rev.41(4) , 573–643 (2009).
   PubMed Web of Science ®Google Scholar
• Daly AK , BrockmollerJ, BrolyF et al.: Nomenclature for human CYP2D6 alleles.Pharmacogenetics6(3) , 193–201 (1996).
   PubMedGoogle Scholar
• Zhou SF : Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I.Clin. Pharmacokinet.48(11) , 689–723 (2009).
   PubMed Web of Science ®Google Scholar
• Maddocks I , SomogyiA, AbbottF, HayballP, ParkerD: Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.J. Pain Symptom Manage.12 , 182–189 (1996).
   PubMed Web of Science ®Google Scholar
• Gasche Y , DaaliY, FathiM et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism.N. Engl. J. Med.351(27) , 2827–2831 (2004).
   PubMed Web of Science ®Google Scholar
• Susce MT , Murray-CarmichaelE, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry30(7) , 1356–1358 (2006).
   PubMed Web of Science ®Google Scholar
• Koren G , CairnsJ, ChitayatD, GaedigkA, LeederSJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.Lancet368(9536) , 704 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou SF : Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Clin. Pharmacokinet.48(12) , 761–804 (2009).
   PubMed Web of Science ®Google Scholar
• Williams DG , HatchDJ, HowardRF: Codeine phosphate in paediatric medicine.Br. J. Anaesth.86(3) , 413–421 (2001).
   PubMed Web of Science ®Google Scholar
• Thorn CF , KleinTE, AltmanRB. Codeine and morphine pathway. Pharmacogenet. Genomics19(7) , 556–558 (2009).
   PubMed Web of Science ®Google Scholar
• Lötsch J , GeisslingerG, TegederI. Genetic modulation of the pharmacological treatment of pain. Pharmacol. Ther.124(2) , 168–184 (2009).
   PubMed Web of Science ®Google Scholar
• Poulsen L , BrosenK, Arendt-NielsenL, GramLF, ElbaekK, SindrupSH: Codeine and morphine in extensive and poor metabolisers of sparteine: pharmacokinetics, analgesic effect and side effects.Eur. J. Clin. Pharmacol.51(3–4) , 289–295 (1996).
   PubMed Web of Science ®Google Scholar
• Persson K , SjöströmS, SigurdardottirI et al.: Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan.Br. J. Clin. Pharmacol.39(2) , 182–186 (1995).
   PubMed Web of Science ®Google Scholar
• Williams DG , PatelA, HowardRF: Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability.Br. J. Anaesth.89(6) , 839–845 (2002).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , SchmidtH, TzvetkovM et al.: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolisers due to CYP2D6 duplication.Pharmacogenomics J.7(4) , 257–265 (2007).
   PubMed Web of Science ®Google Scholar
• Lötsch J , RohrbacherM, SchmidtH, DoehringA, BrockmöllerJ, GeisslingerG: Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?Pain144(1–2) , 119–124 (2009).
   PubMed Web of Science ®Google Scholar
• Ciszkowski C , MadadiP, PhillipsMS, LauwersAE, KorenG: Codeine, ultrarapid-metabolism genotype, and postoperative death.N. Engl. J. Med.361(8) , 827–828 (2009).
   PubMed Web of Science ®Google Scholar
• Voronov P , PrzybyloHJ, JagannathanN: Apnea in a child after oral codeine: a genetic variant – an ultra-rapid metabolizer.Paediatr. Anaesth.17(7) , 684–887 (2007).
   PubMed Web of Science ®Google Scholar
• Madadi P , KorenG, CairnsJ et al.: Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine.Can. Fam. Physician53(1) , 33–35 (2007).
   PubMedGoogle Scholar
• Madadi P , ShiraziF, WalterFG, KorenG: Establishing causality of CNS depression in breastfed infants following maternal codeine use.Paediatr. Drugs10(6) , 399–404 (2008).
   PubMedGoogle Scholar
• Madadi P , RossCJ, HaydenMR et al.: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study.Clin. Pharmacol. Ther.85(1) , 31–35 (2009).
   PubMed Web of Science ®Google Scholar
• Fromm MF , HofmannU, GrieseEU, MikusG: Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.Clin. Pharmacol. Ther.58(4) , 374–382 (1995).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH , HufschmidE, ThormannW: The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers.Br. J. Clin. Pharmacol.45(6) , 575–581 (1998).
   PubMed Web of Science ®Google Scholar
• Schmidt H , VormfeldeSV, Walchner-BonjeanM et al.: The role of active metabolites in dihydrocodeine effects.Int. J. Clin. Pharmacol. Ther.41(3) , 95–106 (2003).
   PubMed Web of Science ®Google Scholar
• Otton SV , SchadelM, CheungSW et al.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.Clin. Pharmacol. Ther.54(5) , 463–472 (1993).
   PubMed Web of Science ®Google Scholar
• Hutchinson MR , MenelaouA, FosterDJ, CollerJK, SomogyiAA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.Br. J. Clin. Pharmacol.57(3) , 287–297 (2004).
   PubMed Web of Science ®Google Scholar
• Kaplan HL , BustoUE, BaylonGJ et al.: Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.J. Pharmacol. Exp. Ther.281(1) , 103–108 (1997).
   PubMed Web of Science ®Google Scholar
• Scott LJ , PerryCM: Tramadol: a review of its use in perioperative pain.Drugs60(1) , 139–176 (2000).
   PubMed Web of Science ®Google Scholar
• Lai J , MaSW, PorrecaF, RaffaRB: Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells.Eur. J. Pharmacol.316(2–3) , 369–372 (1996).
   PubMed Web of Science ®Google Scholar
• Enggaard TP , PoulsenL, Arendt-NielsenL, Br⊘senK, OssigJ, SindrupSH: The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.Anesth. Analg.102(1) , 146–150 (2006).
   PubMed Web of Science ®Google Scholar
• Stamer UM , LehnenK, HöthkerF et al.: Impact of CYP2D6 genotype on postoperative tramadol analgesia.Pain105(1–2) , 231–238 (2003).
   PubMed Web of Science ®Google Scholar
• Wang G , ZhangH, HeF, FangX: Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population.Eur. J. Clin. Pharmacol.62(11) , 927–931 (2006).
   PubMed Web of Science ®Google Scholar
• Pedersen RS , DamkierP, Br⊘senK: Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.Eur. J. Clin. Pharmacol.62(7) , 513–521 (2006).
   PubMed Web of Science ®Google Scholar
• Stamer UM , MusshoffF, KobilayM, MadeaB, HoeftA, StüberF: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.Clin. Pharmacol. Ther.82(1) , 41–47 (2007).
   PubMed Web of Science ®Google Scholar
• García-Quetglas E , AzanzaJR, SádabaB, MuñozMJ, GilI, CampaneroMA: Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.Pharmacol. Res.55(2) , 122–130 (2007).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , KeulenJT, BauerS, RootsI, BrockmöllerJ: Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.J. Clin. Psychopharmacol.28(1) , 78–83 (2008).
   PubMed Web of Science ®Google Scholar
• Stamer UM , StüberF, MudersT, MusshoffF: Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.Anesth. Analg.107(3) , 926–929 (2008).
   PubMed Web of Science ®Google Scholar
• Lalovic B , KharashE, HofferC, RislerL, Liu-ChenLY, ShenDD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating metabolites.Clin. Pharmacol. Ther.79(5) , 461–479 (2006).
   PubMed Web of Science ®Google Scholar
• Lemberg KK , HeiskanenTE, NeuvonenM et al.: Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients.Scandinavian J. Pain1 , 24–33 (2010).
   PubMedGoogle Scholar
• Zwisler ST , EnggaardTP, MikkelsenS, BrosenK, SindrupSH: Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.Acta Anaesthesiol. Scand.54(2) , 232–240 (2010).
   PubMed Web of Science ®Google Scholar
• Zwisler ST , EnggaardTP, Noehr-JensenL et al.: The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.Basic Clin. Pharmacol. Toxicol.104(4) , 335–344 (2009).
   PubMed Web of Science ®Google Scholar
• Nieminen TH , HagelbergNM, SaariTI et al.: Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.Anesthesiology110(6) , 1371–1378 (2009).
   PubMed Web of Science ®Google Scholar
• Shaiova L , BergerA, BlindermanCD et al.: Consensus guideline on parenteral methadone use in pain and palliative care.Palliat. Support. Care6(2) , 165–176 (2008).
   PubMedGoogle Scholar
• Bruera E , SweeneyC: Methadone use in cancer patients with pain: a review.J. Palliat. Med.5(1) , 127–138 (2002).
   PubMedGoogle Scholar
• Crettol S , DéglonJJ, BessonJ et al.: ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.Clin. Pharmacol. Ther.80(6) , 668–681 (2006).
   PubMed Web of Science ®Google Scholar
• Lötsch J , SkarkeC, WietingJ et al.: Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.Clin. Pharmacol. Ther.79(1) , 72–89 (2006).
   PubMed Web of Science ®Google Scholar
• de los Cobos J , ValeroS, HaroG et al.: Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT).Drug Alcohol Depend.68(2) , 209–214 (2002).
   PubMed Web of Science ®Google Scholar
• Coller JK , JoergensenC, FosterDJ et al.: Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.Int. J. Clin. Pharmacol. Ther.45(7) , 410–417 (2007).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , NickchenK, BauerM et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry9(5) , 442–473 (2004).
   PubMed Web of Science ®Google Scholar
• Steimer W , ZöpfK, von Amelunxen S et al.: Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem.51(2) , 376–385 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou SF , ZhouZW, HuangM: Polymorphisms of human cytochrome P450 2C9 and the functional relevance.Toxicology (2009) (Epub ahead of print).
   Web of Science ®Google Scholar
• Kirchheiner J , BrockmöllerJ: Clinical consequences of cytochrome P450 2C9 polymorphisms.Clin. Pharmacol. Ther.77(1) , 1–16 (2005).
   PubMed Web of Science ®Google Scholar
• Rodrigues AD : Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?Drug Metab. Dispos.33(11) , 1567–1575 (2005).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , StörmerE, MeiselC, SteinbachN, RootsI, BrockmollerJ: Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.Pharmacogenetics13(8) , 473–480 (2003).
   PubMedGoogle Scholar
• Pilotto A , SeripaD, FranceschiM et al.: Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.Gastroenterology133(2) , 465–471 (2007).
   PubMed Web of Science ®Google Scholar
• Dorado P , BereczR, NorbertoMJ et al.: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.Eur. J. Clin. Pharmacol.59(3) , 221–225 (2003).
   PubMed Web of Science ®Google Scholar
• Tang C , ShouM, RushmoreTH et al.: In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.Pharmacogenetics11(3) , 223–235 (2001).
   PubMedGoogle Scholar
• Kirchheiner J , MeinekeI, FreytagG, MeiselC, RootsI, BrockmollerJ: Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.Clin. Pharmacol. Ther.72(1) , 62–75 (2002).
   PubMed Web of Science ®Google Scholar
• Martínez C , García-MartínE, BlancoG, GamitoFJ, LaderoJM, AgúndezJA: The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.Br. J. Clin. Pharmacol.59(1) , 62–69 (2005).
   PubMed Web of Science ®Google Scholar
• García-Martín E , MartínezC, TabarésB, FríasJ, AgúndezJA: Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.Clin. Pharmacol. Ther.76(2) , 119–127 (2004).
   PubMed Web of Science ®Google Scholar
• Vianna-Jorge R , PeriniJA, RondinelliE, Suarez-KurtzG: CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.Clin. Pharmacol. Ther.76(1) , 18–26 (2004).
   PubMed Web of Science ®Google Scholar
• Peiró AM , NovalbosJ, ZapaterP et al.: Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.Pharmacol. Res.59(1) , 62–68 (2009).
   PubMed Web of Science ®Google Scholar
• Perini JA , Vianna-JorgeR, BrogliatoAR, Suarez-KurtzG: Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.Clin. Pharmacol. Ther.78(4) , 362–369 (2005).
   PubMed Web of Science ®Google Scholar
• Guo Y , ZhangY, WangY et al.: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.Drug Metab. Dispos.33(6) , 749–753 (2005).
   PubMed Web of Science ®Google Scholar
• Liu YL , ZhangW, TanZR et al.: Effect of the CYP2C9*3 allele on lornoxicam metabolism.Clin. Chim. Acta364(1–2) , 287–291 (2006).
   PubMed Web of Science ®Google Scholar
• Dorado P , CavacoI, CáceresMC, PiedadeR, RibeiroV, LlerenaA: Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.Eur. J. Clin. Pharmacol.64(10) , 967–970 (2008).
   PubMed Web of Science ®Google Scholar
• Daily EB , AquilanteCL: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.Pharmacogenomics10(9) , 1489–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Visser LE , van Vliet M, van Schaik RH et al.: The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics14(1) , 27–33 (2004).
   PubMedGoogle Scholar
• Pilotto A , FranceschiM, VitaleDF et al.: Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs.Aliment. Pharmacol. Ther.22(2) , 147–155 (2005).
   PubMed Web of Science ®Google Scholar
• Blanco G , MartínezC, LaderoJM: Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.Pharmacogenet. Genomics18(1) , 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Vonkeman HE , van de Laar MA, van der Palen J, Brouwers JR, Vermes I: Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther.28(10) , 1670–1676 (2006).
   PubMed Web of Science ®Google Scholar
• Ma J , YangXY, QiaoL, LiangLQ, ChenMH: CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.J. Dig. Dis.9(2) , 79–83 (2008).
   PubMed Web of Science ®Google Scholar
• Agúndez JA , García-MartínE, MartínezC: Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Expert Opin. Drug Metab. Toxicol.5(6) , 607–620 (2009).
   PubMed Web of Science ®Google Scholar
• Harder S , ThürmannP: Clinically important drug interactions with anticoagulants. An update.Clin. Pharmacokinet.30(6) , 416–444 (1996).
   PubMed Web of Science ®Google Scholar
• Visser LE , van Schaik RH, van Vliet M et al.: Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin. Pharmacol. Ther.77(6) , 479–485 (2005).
   PubMed Web of Science ®Google Scholar
• Park HJ , ShinnHK, RyuSH, LeeHS, ParkCS, KangJH: Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans.Clin. Pharmacol. Ther.81(4) , 539–546 (2007).
   PubMed Web of Science ®Google Scholar
• Zwisler ST , EnggaardTP, Noehr-JensenL et al.: The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes.Fundam. Clin. Pharmacol. (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Campa D , GioiaA, TomeiA, PoliP, BaraleR: Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.Clin. Pharmacol. Ther.83(4) , 559–566 (2008).
   PubMed Web of Science ®Google Scholar
• Lötsch J , von Hentig N, Freynhagen R et al.: Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics19(6) , 429–436 (2009).
   PubMed Web of Science ®Google Scholar
• Levran O , O‘HaraK, PelesE et al.: ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.Hum. Mol. Genet.17(14) , 2219–2227 (2008).
   PubMed Web of Science ®Google Scholar
• Coller JK , BarrattDT, DahlenK, LoennechenMH, SomogyiAA: ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.Clin. Pharmacol. Ther.80(6) , 682–690 (2006).
   PubMed Web of Science ®Google Scholar
• Crettol S , DéglonJJ, BessonJ et al.: No influence of ABCB1 haplotypes on methadone dosage requirement.Clin. Pharmacol. Ther.83(5) , 668–669 (2008).
   PubMed Web of Science ®Google Scholar
• Lee YS , KimH, WuTX, WangXM, DionneRA: Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs.Clin. Pharmacol. Ther.79(5) , 407–418 (2006).
   PubMed Web of Science ®Google Scholar
• Skarke C , ReusM, SchmidtR et al.: The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.Clin. Pharmacol. Ther.80(6) , 621–632 (2006).
   PubMed Web of Science ®Google Scholar
• Ono T , MutoA, KanedaT, AritaE, YoshidaT: Novel linkage disequilibrium of single nucleotide polymorphisms in the transcriptional regulatory region of micro-opioid receptor gene in Japanese population.Biol. Pharm. Bull.32(4) , 721–773 (2009).
   PubMed Web of Science ®Google Scholar
• Chou WY , YangLC, LuHF et al.: Association of µ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty.Acta Anaesthesiol. Scand.50(7) , 787–792 (2006).
   PubMed Web of Science ®Google Scholar
• Chou WY , WangCH, LiuPH, LiuCC, TsengCC, JawanB: Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy.Anesthesiology105(2) , 334–337 (2006).
   PubMed Web of Science ®Google Scholar
• Oertel BG , KettnerM, ScholichK et al.: A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.J. Biol. Chem.284(10) , 6530–6535 (2009).
   PubMed Web of Science ®Google Scholar
• Klepstad P , RakvagTT, KaasaS et al.: The 118 A > G polymorphism in the human µ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.Acta Anaesthesiol. Scand.48(10) , 1232–1239 (2004).
   PubMed Web of Science ®Google Scholar
• Walter C , LötschJ: Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.Pain146(3) , 270–275 (2009).
   PubMed Web of Science ®Google Scholar
• Janicki PK , SchulerG, FrancisD et al.: A genetic association study of the functional A118G polymorphism of the human µ-opioid receptor gene in patients with acute and chronic pain.Anesth. Analg.103(4) , 1011–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Coulbault L , BeaussierM, VerstuyftC et al.: Environmental and genetic factors associated with morphine response in the postoperative period.Clin. Pharmacol. Ther.79(4) , 316–324 (2006).
   PubMed Web of Science ®Google Scholar
• Huehne K , LeisS, MuensterT et al.: High post surgical opioid requirements in Crohn‘s disease are not due to a general change in pain sensitivity.Eur. J. Pain13(10) , 1036–1042 (2009).
   PubMed Web of Science ®Google Scholar
• Landau R , KernC, ColumbMO, SmileyRM, BlouinJL: Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women.Pain139(1) , 5–14 (2008).
   PubMed Web of Science ®Google Scholar
• Landau R : One size does not fit all: genetic variability of µ-opioid receptor and postoperative morphine consumption.Anesthesiology105(2) , 235–237 (2006).
   PubMed Web of Science ®Google Scholar
• Lötsch J . Basic genetic statistics are necessary in studies of functional association in anesthesiology. Anesthesiology107 , 168–169 (2007).
   PubMed Web of Science ®Google Scholar
• Chanock SJ , ManolioT, BoehnkeM et al.; NCI-NHGRI Working Group on Replication in Association Studies: Replicating genotype–phenotype associations. Nature447(7145) , 655–660 (2007).
   PubMed Web of Science ®Google Scholar
• Zubieta JK , HeitzegMM, SmithYR et al.: Val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.Science299(5610) , 1240–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Rakvåg TT , KlepstadP, BaarC et al.: The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain116(1–2) , 73–78 (2005).
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC , SheteS, RakvågT et al.: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.Pain130(1–2) , 25–30 (2007).
   PubMed Web of Science ®Google Scholar
• Kim H , NeubertJK, San Miguel A et al.: Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain109(3) , 488–496 (2004).
   PubMed Web of Science ®Google Scholar
• Kim H , LeeH, RowanJ, BrahimJ, DionneRA: Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans.Mol. Pain.18(2) , 24 (2006).
   Google Scholar
• Birklein F , DepmeierC, RolkeR et al.: A family-based investigation of cold pain tolerance.Pain138(1) , 111–118 (2008).
   PubMed Web of Science ®Google Scholar
• Rakvåg TT , RossJR, SatoH, SkorpenF, KaasaS, KlepstadP: Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain.Mol. Pain.18(4) , 64 (2008).
   Google Scholar
• Ross JR , RileyJ, TaegetmeyerAB et al.: Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.Cancer112(6) , 1390–1403 (2008).
   PubMed Web of Science ®Google Scholar
• Lacroix-Fralish ML , MogilJS. Progress in genetic studies of pain and analgesia. Annu. Rev. Pharmacol. Toxicol.49 , 97–121 (2009).
   PubMed Web of Science ®Google Scholar
• Kim H , ClarkD, DionneRA: Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research.J. Pain10(7) , 663–693 (2009).
   PubMed Web of Science ®Google Scholar
• Lötsch J , FlührK, NeddermayerT, DoehringA, GeisslingerG: The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain.Clin. Pharmacol. Ther.85(1) , 25–30 (2009).
   PubMed Web of Science ®Google Scholar
• Kim H , RamsayE, LeeH, WahlS, DionneRA: Genome-wide association study of acute post-surgical pain in humans.Pharmacogenomics10(2) , 171–179 (2009).
   PubMed Web of Science ®Google Scholar
• Tegeder I , LötschJ: Current evidence for a modulation of low back pain by human genetic variants.J. Cell Mol. Med. (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Somogyi AA , BarrattDT, CollerJK: Pharmacogenetics of opioids.Clin. Pharmacol. Ther.81(3) , 429–444 (2007).
   PubMed Web of Science ®Google Scholar
• Slade GD , DiatchenkoL, BhalangK et al.: Influence of psychological factors on risk of temporomandibular disorders.J. Dent. Res.86(11) , 1120–1125 (2007).
   PubMed Web of Science ®Google Scholar
• George SZ , WallaceMR, WrightTW et al.: Evidence for a biopsychosocial influence on shoulder pain: pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings.Pain136(1–2) , 53–61 (2008).
   PubMed Web of Science ®Google Scholar
• Hapgood R : The potential and limitations of personalized medicine in the doctor-patient relationship.Pharmacogenomics4(6) , 685–687 (2003).
   PubMed Web of Science ®Google Scholar
• López-Rodríguez R , NovalbosJ, Gallego-SandínS et al.: Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.Pharmacol. Res.58(1) , 77–84 (2008).
   PubMed Web of Science ®Google Scholar
• Bae JW , KimJH, ChoiCI et al: Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch. Pharm. Res.32(2) , 269–273 (2009).
   PubMed Web of Science ®Google Scholar
• Huang CJ , LiuHF, SuNY et al.: Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females.Anaesthesia63(12) , 1288–1295 (2008).
   PubMed Web of Science ®Google Scholar
• Sia AT , LimY, LimEC et al.: A118G single nucleotide polymorphism of human µ-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia.Anesthesiology109(3) , 520–526 (2008).
   PubMed Web of Science ®Google Scholar
• Hayashida M , NagashimaM, SatohY et al.: Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype.Pharmacogenomics9(11) , 1605–1616 (2008).
   PubMed Web of Science ®Google Scholar
• Fukuda K , HayashidaM, IdeS et al.: Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery.Pain147(1–3) , 194–201 (2009).
   PubMed Web of Science ®Google Scholar
• Tan EC , LimEC, TeoYY, LimY, LawHY, SiaAT: Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain.Mol. Pain.23(5) , 32 (2009).
   Google Scholar
• Wu WD , WangY, FangYM, ZhouHY: Polymorphism of the mu-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery.Mol. Diagn. Ther.13(5) , 331–337 (2009).
   PubMed Web of Science ®Google Scholar
• Ginosar Y , DavidsonEM, MerozY, BlotnickS, ShachamM, CaracoY: Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic–pharmacodynamic study.Br. J. Anaesth.103(3) , 420–427 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Flockhart DA: Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007) http://medicine.iupui.edu/clinpharm/ddis/table.asp (Accessed November2009)
   Google Scholar
• Home Page of the CYP Allele Nomenclature Committee www.imm.ki.se/CYPalleles/ (Accessed November2009)
   Google Scholar
• NCBI SNP database www.ncbi.nlm.nih.gov/SNP (Accessed November2009)
   Google Scholar